Dyspepsia - Pipeline Insight, 2024

This “Dyspepsia- Pipeline Insight, 2024” report provides comprehensive insights about 2+ companies and 2+ pipeline drugs in Dyspepsia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Dyspepsia: Understanding

Dyspepsia: Overview

Dyspepsia is upper abdominal pain or discomfort that is episodic or persistent and often associated with belching, bloating, heartburn and nausea or vomiting. Dyspepsia can be divided into 2 main categories: organic and functional dyspepsia (FD). Organic causes of dyspepsia are peptic ulcer, gastroesophageal reflux disease, gastric or esophageal cancer, pancreatic or biliary disorders, intolerance to food or drugs, and other infectious or systemic diseases. Pathophysiological mechanisms underlying FD are delayed gastric emptying, impaired gastric accommodation to a meal, hypersensitivity to gastric distension, altered duodenal sensitivity to lipids or acids, altered antroduodenojenunal motility and gastric electrical rhythm, unsuppressed postprandial phasic contractility in the proximal stomach, and autonomic nervous system-central nervous system dysregulation.

The condition is reported to occur in approximately 25 percent (range: 13 to 40 percent) of the population each year, but most affected persons do not seek medical care. Even though dyspepsia is a highly prevalent condition, no definitive studies have as yet established guidelines for the work-up of dyspeptic patients in the primary care setting. Dyspepsia, often defined as chronic or recurrent discomfort centered in the upper abdomen, can be caused by a variety of conditions. Common etiologies include peptic ulcers and gastroesophageal reflux. Serious causes, such as gastric and pancreatic cancers, are rare but must also be considered. Symptoms of possible causes often overlap, which can make initial diagnosis difficult. In many patients, a definite cause is never established. The initial evaluation of patients with dyspepsia includes a thorough history and physical examination, with special attention given to elements that suggest the presence of serious disease. Endoscopy should be performed promptly in patients who have “alarm symptoms” such as melena or anorexia.

Optimal management remains controversial in young patients who do not have alarm symptoms. Because the differential diagnosis of dyspepsia is broad, initial efforts should be focused on the most common etiologies. In about 50 to 60 percent of patients, a specific etiology is not identified (i.e., “functional” or nonulcer dyspepsia). All patients with dyspepsia should be advised to stop smoking and, if their medical condition permits, to discontinue ulcerogenic medications. They should also avoid foods and other factors that precipitate their symptoms. Because dyspepsia may be aggravated by stress, anxiety or depression, it may be useful to explore these issues. Reassurance is a key step in managing dyspepsia, but advice regarding stress-reducing activities such as exercise and relaxation is also important.

Dyspepsia- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Dyspepsia pipeline landscape is provided which includes the disease overview and Dyspepsia treatment guidelines. The assessment part of the report embraces, in depth Dyspepsia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Dyspepsia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Dyspepsia R&D. The therapies under development are focused on novel approaches to treat/improve Dyspepsia.

Dyspepsia Emerging Drugs Chapters

This segment of the Dyspepsia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Dyspepsia Emerging Drugs

Tradipitant (VLY-686) : Vanda Pharmaceuticals Tradipitant (VLY-686) is a novel investigative small molecule. The drug candidate is a new chemical entity that targets neurokinin-1 (NK-1) receptor. It works by blocking substance P, a small signaling molecule. Originally, this compound was owned by Eli Lilly and named LY686017. VLY-686 was purchased by Vanda Pharmaceuticals from Eli Lilly and Company in 2012. Currently, the drug is in Phase II stage of its development for the treatment of dyspepsia.

Dyspepsia: Therapeutic Assessment

This segment of the report provides insights about the different Dyspepsia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Dyspepsia

• There are approx. 2+ key companies which are developing the therapies for Dyspepsia. The companies which have their Dyspepsia drug candidates in the most advanced stage, i.e. phase III include, Vanda Pharmaceuticals.

Phases

This report covers around 2+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Dyspepsia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Dyspepsia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Dyspepsia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dyspepsia drugs.

Dyspepsia Report Insights

• Dyspepsia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Dyspepsia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Dyspepsia drugs?
• How many Dyspepsia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Dyspepsia?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Dyspepsia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Dyspepsia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Vanda Pharmaceuticals
• Dong-A ST Co., Ltd.
• Dexa Medica Group

Key Products

• Tradipitant
• DA-5212
• DLBS2411

This product will be delivered within 2 business days.